← All trials
NCT05128175
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2021
- Primary completion
- Jan 25, 2022
- Completion date
- Mar 25, 2022
- First posted
- Nov 19, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 15
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of ChinaLead sponsor
- Lambda Therapeutic Research LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.